Quick Answer
PLUS THERAPEUTICS, INC. reported Research And Development Expense of $8.38 million for the year ending 2025.
- PLUS THERAPEUTICS, INC. showed a decrease of -20.8% in Research And Development Expense from 2024 to 2025.
- This data is from PLUS THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2009 to 2025), PLUS THERAPEUTICS, INC.'s Research And Development Expense has declined by 31.5%.
- Historical annual values: Fiscal year 2025: $8.38 million | Fiscal year 2024: $10.58 million | Fiscal year 2023: $9.69 million | Fiscal year 2022: $9.70 million | Fiscal year 2020: $2.70 million | Fiscal year 2019: $5.37 million | Fiscal year 2018: $5.52 million | Fiscal year 2017: $11.68 million | Fiscal year 2016: $16.20 million | Fiscal year 2015: $19.00 million | Fiscal year 2014: $15.11 million | Fiscal year 2013: $17.07 million | Fiscal year 2012: $13.63 million | Fiscal year 2011: $10.90 million | Fiscal year 2010: $9.69 million | Fiscal year 2009: $12.23 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: